Physician profile
Jon-Michael Cook
NPI 1467891143
$7,023.23
in general payments reported to CMS, 2019-2025
45 companies · $2,252 in 2025
The $2,252 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,041 · 2020: $197 · 2021: $64.57 · 2022: $485 · 2023: $1,295 · 2024: $1,688 · 2025: $2,252.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,235.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,234.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $930.07 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals Lp | $765.27 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Abbvie INC. | $671.44 | 2022-2025 | Vraylar, Ubrelvy, Qulipta |
| Pfizer INC. | $597.65 | 2019-2025 | |
| Amgen INC. | $428.81 | 2019-2025 | Repatha, Otezla, Evenity |
| Lilly USA, LLC | $403.22 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $317.07 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Abbott Laboratories | $261.81 | 2022-2025 | Freestyle Libre 3, Freestyle Libre 2, Eterna |
| Boehringer Ingelheim Pharmaceuticals, INC. | $244.97 | 2019-2025 | Jardiance |
| Exact Sciences Corporation | $242.16 | 2023-2025 | Cologuard Collection Kit |
| Amarin Pharma, INC. | $219.67 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $175.96 | 2024-2025 | Rexulti |
| Astellas Pharma US INC | $160.73 | 2024-2025 | Veozah |
| Sanofi-Aventis U.S. LLC | $133.82 | 2019-2025 | |
| Viiv Healthcare Company | $133.81 | 2024-2025 | Apretude |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $120.60 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $119.34 | 2019-2025 | Xifaxan, Trulance |
| Dexcom, INC. | $100.56 | 2024-2025 | Dexcom G6 Transmitter, Dexcom G7 Gss (161), Dexcom Stelo Glucose Biosensor |
| Merck Sharp & Dohme LLC | $91.73 | 2019-2023 | M-M-R II, Gardasil 9, Vaxneuvance |
| Azurity Pharmaceuticals, INC. | $76.04 | 2024-2025 | Edarbyclor, Horizant |
| Welch Allyn | $64.57 | 2021 | |
| Janssen Pharmaceuticals, INC | $64.17 | 2019-2023 | Spravato |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $58.46 | 2025 | Caplyta |
| Boston Scientific Corporation | $54.48 | 2025 | Wavewriter Alpha Prime 16 |
| Phathom Pharmaceuticals, INC. | $54.38 | 2025 | Voquezna |
| Bayer Healthcare Pharmaceuticals INC. | $53.61 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $47.68 | 2019 | |
| Inspire Medical Systems, INC. | $46.22 | 2024-2025 | Inspire |
| Tolmar, INC. | $43.45 | 2025 | Jatenzo |
| Dynavax Technologies Corporation | $43.17 | 2023 | Heplisav-B |
| Medtronic, INC. | $32.15 | 2023-2024 | Venaseal, Intellis Adaptivestim |
| Seqirus USA INC | $31.12 | 2022-2024 | Fluad, Flucelvax |
| Idorsia Pharmaceuticals US INC | $28.34 | 2023 | Quviviq |
| Lundbeck LLC | $24.98 | 2025 | Rexulti |
| Xeris Pharmaceuticals, INC. | $22.93 | 2025 | Recorlev |
| Tris Pharma INC | $22.59 | 2023 | Dyanavel Xr |
| Biohaven Pharmaceutical Holding Company Ltd. | $18.41 | 2022 | |
| Qol Medical, LLC | $17.87 | 2019 | |
| Novartis Pharmaceuticals Corporation | $17.32 | 2022 | |
| Corcept Therapeutics | $16.77 | 2025 | Korlym |
| Kowa Pharmaceuticals America, INC. | $15.37 | 2025 | Zoryve |
| Noven Therapeutics, LLC | $13.99 | 2023 | Xelstrym |
| Nalpropion Pharmaceuticals LLC | $13.15 | 2019 | |
| Allergan, INC. | $11.80 | 2019 | |
| Currax Pharmaceuticals LLC | $11.52 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jon-Michael Cook listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.